Oral antidiabetic agents: how much kidney disease can we tolerate?

References

• UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with Type 2 diabetes (UKPDS 34). Lancet352, 854–865 (1998).
   PubMed Web of Science ®Google Scholar
• Dormandy JA, Charbonnel B, Eckland DJ et al. Secondary prevention of macrovascular events in patients with Type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet366, 1279–1289 (2005).
   PubMed Web of Science ®Google Scholar
• Kong AP, So WY, Szeto CC et al. Assessment of glomerular filtration rate in addition to albuminuria is important in managing Type II diabetes. Kidney Int.69, 383–387 (2006).
   Google Scholar
• Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am. J. Kidney Dis.32, 112–119 (1998).
   PubMed Web of Science ®Google Scholar
• Levey AS, Bosch JP, Lewis JP, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann. Intern. Med.130, 461–470 (1999).
   PubMed Web of Science ®Google Scholar
• Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron16, 31–41 (1976).
   PubMed Web of Science ®Google Scholar
• National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am. J. Kidney Dis.39, S1–S266 (2002).
   PubMed Web of Science ®Google Scholar
• Levey AS, Eckardt KU, Tsukamoto Y et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int.67, 2089–2100 (2005).
   PubMed Web of Science ®Google Scholar
• National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am. J. Kidney Dis.49(Suppl. 2), S1–S180 (2007).
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standard of medical care in diabetes 2006. Diabetes Care29(Suppl. 1), 4–34 (2006).
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet352, 837–853 (1998).
   PubMed Web of Science ®Google Scholar
• Stratton IM, Adler AI, Neil HA et al. UK Prospective Diabetes Study Group: association of glycaemia with macrovascular and microvascular complications of Type 2 diabetes (UKPDS 35): prospective observational study. Br. Med. J.321, 405–412 (2000).
   PubMed Web of Science ®Google Scholar
• Nathan DM, Buse JB, Davidson MB et al. Management of hyperglycaemia in Type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetologica49, 1711–1721 (2006).
   PubMed Web of Science ®Google Scholar
• Yale JF. Oral antihyperglycemic agents and renal disease: new agents, new concepts. J. Am. Soc. Nephrol.16(Suppl. 1), S7–S10 (2005).
   PubMedGoogle Scholar
• Bailey CJ, Turner RC. Metformin. N. Engl. J. Med.334, 574–579 (1996).
   PubMed Web of Science ®Google Scholar
• Schäfer G. Some new aspects of the interaction of hypoglycaemia producing biguanides with biological membrane. Biochem. Pharmacol.25, 2075–2076 (1976).
   Google Scholar
• Douek IF, Allen SE, Ewings P, Gale EA, Bingley PJ; the Metformin Trial Group. Continuing metformin when starting insulin in patients with Type 2 diabetes: a double blind randomized placebo-controlled trial. Diabet. Med.22, 634–640 (2005).
   PubMed Web of Science ®Google Scholar
• Stang MR, Wysowski DK, Butler-Jones D. Incidence of lactic acidosis in metformin users. Diabetes Care22>, 925–927 (1999).
   PubMed Web of Science ®Google Scholar
• Brown JB, Pedula K, Barzilay J, Herson MK, Latare P. Lactic acidosis rates in Type 2 diabetes. Diabetes Care21, 1659–1663 (1998).
   PubMed Web of Science ®Google Scholar
• Holstein A, Stumvoll M. Contraindications can damage your health – is metformin a case in point? Diabetologica48, 2454–2459 (2005).
   PubMed Web of Science ®Google Scholar
• Gan SC, Barr J, Arieff AI, Pearl RG. Biguanid-associated lactic acidosis. Case report and review of the literature. Arch. Intern. Med.152, 2333–2336 (1992).
   PubMed Web of Science ®Google Scholar
• Gudmundsdottir H, Asknes H, Heldal K et al. Metformin and antihypertensive therapy with drugs blocking the rennin angiotensin system, a cause of concern? Clin. Nephrol.66(5), 380–385 (2006).
   PubMed Web of Science ®Google Scholar
• Stumvoll M, Goldstein BJ, Haeften van TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet365, 1333–1346 (2005).
   PubMed Web of Science ®Google Scholar
• Krepinsky J, Ingram AJ, Clase CM. Prolonged sulfonylurea-induced hypoglycemia in diabetic patients with end stage renal disease. Am. J. Kidney Dis.35, 500–505 (2000).
   PubMed Web of Science ®Google Scholar
• Shorr RI, Ray WA, Daugherty JR, Griffin MR. Individual sulfonylureas and serious hypoglycemia in older people. J. Am. Geriatr. Soc.44, 751–755 (1997).
   Google Scholar
• Holstein A, Plaschke A, Egberts E-H. Lower incidence of severe hypoglycaemia in patients with Type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab. Res. Rev.17, 467–473 (2001).
   PubMed Web of Science ®Google Scholar
• Schernthaner G, Grimaldi A, Di Mario U et al. GUIDE study: double blind comparison of once-daily gliacide MR and glimepiride in Type 2 diabetic patients. Eur. J. Clin. Invest.34, 535–542 (2004).
   PubMed Web of Science ®Google Scholar
• Balant L, Zahnd G, Gorgia A, Schwarz R, Fabre J. Pharmacokinetics of glipizide in man: influence of renal insufficiency. Diabetologica9(Suppl.), 331–338 (1973).
   Web of Science ®Google Scholar
• Campbell DB. The effects of renal disease on the pharmacokinetics of gliclazide in diabetic patients. Br. J. Clin. Pharmacol.21, 572–573 (1985).
   Google Scholar
• Holstein A, Egberts EH. Risk of hypoglycaemia with oral antidiabetic agents in patients with Type 2 diabetes. Exp. Clin. Endocrinol. Diabetes111, 405–414 (2003).
   PubMed Web of Science ®Google Scholar
• Harrigan RA, Nathan MS, Beattie P. Oral agents for treatment of Type 2 diabetes mellitus: pharmacology, toxicity and treatment. Ann. Emerg. Med.38, 68–78 (2001).
   PubMed Web of Science ®Google Scholar
• Harrower AD. Pharmacokinetics of oral antihyperglycaemic agents in patients with renal insufficiency. Clin. Pharmacokinet.31, 111–119 (1996).
   PubMed Web of Science ®Google Scholar
• Campbell D, Gordon B, Ings R, Beaufils M, Meyrier A, Jones R. The effects of renal disease on the pharmacokinetics of gliclazide in diabetic patients. Br. J. Clin. Pharmacol.21, 572–573 (1985).
   Google Scholar
• Holstein A, Plaschke A, Hammer C, Egberts E-H. Characteristics and time course of severe glimepiride – versus glibenclamide induced hypoglycaemia. Eur. J. Clin. Pharmacol.59, 91–97 (2003).
   PubMed Web of Science ®Google Scholar
• Dornhorst A. Insulinotropic meglitinide analogues. Lancet358, 1709–1716 (2001).
   PubMed Web of Science ®Google Scholar
• Schumacher S, Abbasi I, Weise D et al. Single- and multiple-dose pharmacokinetics of repaglinide in patients with Type 2 diabetes and renal impairment. Eur. J. Clin. Pharmacol.57, 147–152 (2001).
   PubMed Web of Science ®Google Scholar
• Hasslacher C. Safety and efficacy of repaglinide in Type 2 diabetic patients with and without impaired renal function. Diabetes Care26, 886–891 (2003).
   PubMed Web of Science ®Google Scholar
• Chiasson JL, Gomis R, Hanefeld M, Josse RG, Karasik A, Laakso M. The STOP-NIDDM Trial: an international study on the efficacy of an α-glucosidase inhibitor to prevent Type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to prevent non-insulin-dependent diabetes mellitus. Diabetes Care21, 1720–1725 (1998).
   PubMed Web of Science ®Google Scholar
• Charpentier G, Riveline JP, Varroud-Vial M. Management of drugs affecting blood glucose in diabetic patients with renal failure. Diabetes Metab.26(Suppl. 4), 73–85 (2000).
   PubMed Web of Science ®Google Scholar
• Yee HS, Fong NT. A review of the safety and efficacy of acarbose in diabetes mellitus. Pharmacotherapy16, 792–805 (1996).
   Google Scholar
• Reuser AJ, Wisselaar HA. An evaluation of the potential side-effects of α glucosidase inhibitors used for the management of diabetes mellitus. Eur. J. Clin. Invest.24(Suppl. 3), 19–24 (1994).
   PubMedGoogle Scholar
• Chapelsky MC, Thompson-Culkin K, Miller AK, Sack M, Blum R, Freed MI. Pharmacokinetics of rosiglitazone in patients with varying degrees of renal insufficiency. J. Clin. Pharmacol.43, 252–259 (2003).
   PubMed Web of Science ®Google Scholar
• Iglesias P, Dietz JJ. Peroxisome proliferator-activated receptor γ agonists in renal disease. Eur. J. Endocrinol.154, 613–621 (2006).
   PubMed Web of Science ®Google Scholar
• Schernthaner G. Kidney disease in diabetology. Nephrol. Dial. Transplant.22, 703–707 (2007).
   Google Scholar
• Chiang CK, Ho TI, Peng YS et al. Rosiglitazone in diabetes control in hemodialysis patients with and without viral hepatitis infection: effectiveness and side effects. Diabetes Care30, 3–7 (2007).
   PubMed Web of Science ®Google Scholar
• Nesto RW, Bell D, Bonow RO et al. American Heart Association; American Diabetes Association. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association. Circulation108, 2941–2948 (2003).
   PubMed Web of Science ®Google Scholar
• Acomplia® 20 mg, prescribing information. Sanofi-Aventis, Frankfurt, Germany (2006).
   Google Scholar
• Baggio LL, Drucker DJ. Therapeutic approaches to preserve islet mass in Type 2 diabetes. Ann. Rev. Med.57, 265–281 (2006).
   PubMed Web of Science ®Google Scholar
• Januvia™, prescribing information. Merck & Co., Inc., NJ, USA (2006).
   Google Scholar
• Vesco L, Busson M, Bedrossian J, Bitker MO, Hiesse C, Lang P. Diabetes mellitus after renal transplantation. Transplantation61, 1475–1478 (1996).
   PubMed Web of Science ®Google Scholar
• Pietruck F, Kribben A, Van TN et al. Rosiglitazone is a safe and effective treatment option of new-onset diabetes mellitus after renal transplatation. Transplant. Int.18, 483–486 (2005).
   PubMed Web of Science ®Google Scholar
• Luther P, Baldwin D Jr. Pioglitazone in the management of diabetes mellitus after transplantation. Am. J. Transplant.4, 2135–2138 (2004).
   PubMed Web of Science ®Google Scholar